A Phase 1/2 interventional study of Enoxaparin and unfractionated heparin (UFH) in Antithrombotic, sponsored by Bristol-Myers Squibb. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-12-29.
Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To investigate safety of Single Doses of BMS-986177 in Patients with End Stage Renal Disease treated with hemodialysis
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
UFH, BMS-986177 - dose 1, BMS-986177 - dose 2, Enoxaparin
Drug: Enoxaparin · Drug: unfractionated heparin (UFH) · Drug: BMS-986177
BMS-986177 - dose 1, Enoxaparin, UFH, BMS-986177 - dose 2
Drug: Enoxaparin · Drug: unfractionated heparin (UFH) · Drug: BMS-986177
BMS-986177 - dose 2, UFH, Enoxaparin, BMS-986177 - dose 1
Drug: Enoxaparin · Drug: unfractionated heparin (UFH) · Drug: BMS-986177
Enoxaparin, BMS-986177 - dose 2, BMS-986177 - dose 1, UFH
Drug: Enoxaparin · Drug: unfractionated heparin (UFH) · Drug: BMS-986177
Specified dose of Enoxaparin on specified days
Specified dose of UFH on specified days
Specified dose of BMS-986177 on specified day
The Number of Adverse Events (AEs), Serious AEs (SAEs), AEs Leading to Discontinuation and Death
Safety and tolerability of single oral doses of BMS-986177 in patients with end-stage renal disease (ESRD) on chronic hemodialysis (HD) treatment as measured by the number of participants with adverse events (AEs), serious AEs (SAEs), AEs leading to discontinuation and death
Time frame: From the date of patient's written consent to participate in study until 30 days after discontinuation of dosing or patient's participation in study (up to October 2017)
The Number of Participants Marked Abnormalities in Clinical Laboratory Tests : Hematology I; Hematology II; Coagulation
HEMATOLOGY I; HEMOGLOBIN HB G/DL LOW \< 0.85\*PRE-RX; HEMATOCRIT HCT % LOW \< 0.85\*PRE-RX; PLATELET COUNT PLAT X10\*9 C/L LOW \< 0.85\*LLN IF PRE-RX IS MISSING; \< 0.85\*LLN IF PRE-RX \>= LLN; \< 0.85\*PRE-RX IF PRE-RX \< LLN; HIGH \> 1.5\*ULN; HEMATOLOGY II; LEUKOCYTES WBC X10\*3 C/UL LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF LLN \<= PRE-RX \<= ULN; \< 0.85\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.2\*ULN IF PRE-RX IS MISSING; \> 1.2\*ULN IF LLN \<= PRE-RX \<= ULN; \> 1.5\*PRE-RX IF PRE-RX \> ULN; NEUTROPHILS (ABSOLUTE) NEUTA X10\*3 C/UL LOW \< 1.5 IF PRE-RX IS MISSING; \< 1.5 IF PRE-RX \>= 1.5; \< 0.85\*PRE-RX IF; PRE-RX \< 1.5; LYMPHOCYTES (ABSOLUTE) LYMPA X10\*3 C/UL LOW \< 0.75; HIGH \> 7.5; MONOCYTES (ABSOLUTE) MONOA X10\*3 C/UL HIGH \> 2; BASOPHILS (ABSOLUTE) BASOA X10\*3 C/UL HIGH \> 0.4; EOSINOPHILS (ABSOLUTE) EOSA X10\*3 C/UL HIGH \> 0.75; COAGULATION: PROTHROMBIN TIME (PT) PT SEC HIGH \> 1.5\*ULN; APTT APTT SEC HIGH \> 1.5\*ULN; INTL NORMALIZED RATIO (INR) INR FRACTION HIGH \> 1.5\*ULN;
Time frame: At screening; On Day -3 to Day -1, 3 to 6 hours post HD on Days 1, 5, 8, and 12; and at study discharge.
The Number of Marked Abnormalities in Clinical Laboratory Tests (Cont.) : Liver and Kidney Function
LIVER \& KIDNEY FUNCTION; ALKALINE PHOSPHATASE (ALP) ALP U/L HIGH \> 1.25\*ULN IF PRE-RX IS MISSING; \> 1.25\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; ASPARTATE AMINOTRANSFERASE (AST) AST U/L HIGH \> 1.25\*ULN IF PRE-RX IS MISSING; \> 1.25\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; ALANINE AMINOTRANSFERASE (ALT) ALT U/L HIGH \> 1.25\*ULN IF PRE-RX IS MISSING; \> 1.25\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; BILIRUBIN, TOTAL TBILI MG/DL HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; BILIRUBIN, DIRECT DBILI MG/DL HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; BLOOD UREA NITROGEN BUN MG/DL HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.2\*PRE-RX IF PRE-RX \> ULN; CREATININE CREAT MG/DL HIGH \> 1.5\*ULN IF PRE-RX IS MISSING; \> 1.5\*ULN IF PRE-RX \<= ULN; \> 1.33\*PRE-RX IF PRE-RX \> ULN;
Time frame: At screening; On Day -3 to Day -1, 3 to 6 hours post HD on Days 1, 5, 8, and 12; and at study discharge.
The Number of Marked Abnormalities in Clinical Laboratory Tests (Cont.): Electrolytes
ELECTROLYTES: SODIUM, SERUM NA MEQ/L LOW \< 0.95\*LLN IF PRE-RX IS MISSING; \< 0.95\*LLN IF PRE-RX \>= LLN; \< 0.95\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.05\*ULN IF PRE-RX IS MISSING; \> 1.05\*ULN IF PRE-RX \<= ULN; \> 1.05\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN; POTASSIUM, SERUM K MEQ/L LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF PRE-RX \>= LLN; \< 0.9\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.1\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN; CHLORIDE, SERUM CL MEQ/L LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF PRE-RX \>= LLN; \< 0.9\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.1\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN;
Time frame: At screening; On Day -3 to Day -1, 3 to 6 hours post HD on Days 1, 5, 8, and 12; and at study discharge
The Number of Marked Abnormalities in Clinical Laboratory Tests (Cont.): Electrolytes (Cont.)
ELECTROLYTES (CONT.): CALCIUM, TOTAL CA MG/DL LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF PRE-RX \>= LLN; \< 0.9\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.1\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN; PHOSPHORUS, INORGANIC PHOS MG/DL LOW \< 0.85\*LLN IF PRE-RX IS MISSING; \< 0.85\*LLN IF PRE-RX \>= LLN; \< 0.85\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.25\*ULN IF PRE-RX IS MISSING; \> 1.25\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN; MAGNESIUM, SERUM MG MEQ/L LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF PRE-RX \>= LLN; \< 0.9\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.1\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN
Time frame: At screening; On Day -3 to Day -1, 3 to 6 hours post HD on Days 1, 5, 8, and 12; and at study discharge.
The Number of Marked Abnormalities in Clinical Laboratory Tests (Cont.): Other Chemistry Testing
GLUCOSE, FASTING SERUM GLUCF MG/DL LOW \< 0.8\*LLN IF PRE-RX IS MISSING; \< 0.8\*LLN IF PRE-RX \>= LLN; \< 0.8\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.3\*ULN IF PRE-RX IS MISSING \> 1.3\*ULN IF PRE-RX \<= ULN; \> 2\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN; PROTEIN, TOTAL TPRO G/DL LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF PRE-RX \>= LLN; \< 0.9\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.1\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN; ALBUMIN ALB G/DL LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF PRE-RX \>= LLN; \< 0.9\*PRE-RX IF PRE-RX \< LLN; CREATINE KINASE (CK) CK U/L HIGH \> 1.5\*ULN IF PRE-RX IS MISSING; \> 1.5\*ULN IF PRE-RX \<= ULN; \> 1.5\*PRE-RX IF PRE-RX \> ULN; URIC ACID URIC MG/DL HIGH \> 1.2\*ULN IF PRE-RX IS MISSING; \> 1.2\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; LACTATE DEHYDR (LD) LD U/L HIGH \> 1.25\*ULN IF PRE-RX IS MISSING; \> 1.25\*ULN IF PRE-RX \<= ULN; \> 1.5\*PRE-RX IF PRE-RX \> ULN
Time frame: At screening; On Day -3 to Day -1, 3 to 6 hours post HD on Days 1, 5, 8, and 12; and at study discharge.
The Number of Marked Abnormalities in Clinical Laboratory Tests (Cont.) : Urinalysis I, Special Studies
URINALYSIS I; BLOOD, URINE UBLD N/A HIGH \>= 2 IF PRE-RX IS MISSING; \>= 2 IF PRE-RX \< 1; \>= 2 IF PRE-RX \>= 1 SPECIAL STUDIES; OCCULT BLOOD SCREEN, FECES OCBLD N/A HIGH NEGATIVE PRE-RX CHANGING TO POSITIVE
Time frame: At screening; On Day -3 to Day -1, 3 to 6 hours post HD on Days 1, 5, 8, and 12; and at study discharge.
The Change From Baseline in Electrocardiogram (ECG) Parameters: Mean Heart Rate
Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication.
Time frame: Days -3 to -1, Days 1, 5, 8, and 12.
The Change From Baseline in Electrocardiogram (ECG) Parameters: PR Interval, Aggregate
Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication.
Time frame: Days -3 to -1, Days 1, 5, 8, and 12.
The Change From Baseline in Electrocardiogram (ECG) Parameters: QRS Duration, Aggregate
Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication.
Time frame: Days -3 to -1, Days 1, 5, 8, and 12.
The Change From Baseline in Electrocardiogram (ECG) Parameters: QT Interval, Aggregate
Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication.
Time frame: Days -3 to -1, Days 1, 5, 8, and 12.
The Change From Baseline in Electrocardiogram (ECG) Parameters: QTcF Interval, Aggregate
QTcF = QT corrected for heart rate using the Fridericia formula Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication.
Time frame: Days -3 to -1, Days 1, 5, 8, and 12
The Change From Baseline in Vital Signs: Diastolic Blood Pressure
Time frame: Days -3 to -1, 1, 5, 8, 12 and at study discharge on day 13 to day 15
The Change From Baseline in Vital Signs: Systolic Blood Pressure (mm Hg)
Time frame: Days -3 to -1, 1, 5, 8, 12 and at study discharge on day 13 to day 15
The Change From Baseline in Vital Signs: Heart Rate (Beats/Min)
Time frame: Days -3 to -1, 1, 5, 8, 12 and at study discharge on day 13 to day 15
Pharmacokinetic Parameters of BMS-986177: Cmax
Cmax: Maximum observed plasma concentration
Time frame: Either Day 1, 5, 8, or 12 depending on the randomization sequence
Pharmacokinetic Parameters of BMS-986177: Tmax
Time of maximum observed plasma concentration
Time frame: Either Day 1, 5, 8, or 12 depending on the randomization sequence
Pharmacokinetic Parameters of BMS-986177: Area Under the Concentration Curve AUC (0-T), AUC (0-24)
AUC(0-T) Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration AUC(0-24) Area under the plasma concentration-time curve from time zero to 24 hours
Time frame: Either Day 1, 5, 8, or 12 depending on the randomization sequence
Pharmacokinetic Parameters of BMS-986177: fu
Fraction of unbound drug
Time frame: Either Day 1, 5, 8, or 12 depending on the randomization sequence
Pharmacokinetic Parameters of BMS-986177: Cmaxfu
Maximum observed plasma concentration of free drug
Time frame: Either Day 1, 5, 8, or 12 depending on the randomization sequence
Pharmacokinetic Parameters of BMS-986177: Area Under the Concentration Curve AUC (0-T)fu
AUC(0-T)fu Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration of free drug
Time frame: Either Day 1, 5, 8, or 12 depending on the randomization sequence
Pharmacokinetic Parameters of BMS-986177: Area Under the Concentration Curve AUC (3-7)
AUC (3-7) : Area under the plasma concentration-time curve from 3 to 7 hours (ie, during dialysis. Determined from blood samples entering and exiting the dialyzer)
Time frame: Either Day 1, 5, 8, or 12 depending on the randomization sequence
| Milestone | Sequence ABCD | Sequence BDAC | Sequence CADB | Sequence DCBA |
|---|---|---|---|---|
| Started | 7 | 9 | 7 | 9 |
| Completed | 6 | 9 | 7 | 9 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
Safety and tolerability of single oral doses of BMS-986177 in patients with end-stage renal disease (ESRD) on chronic hemodialysis (HD) treatment as measured by the number of participants with adverse events (AEs), serious AEs (SAEs), AEs leading to discontinuation and death
| Participants | Treatment B | Treatment C | Treatment D | Treatment A |
|---|---|---|---|---|
| Adverse Events | 4 | 4 | 3 | 2 |
| Serious Adverse Events | 0 | 0 | 0 | 0 |
| Adverse Events Leading to Discontinuations | 0 | 0 | 0 | 0 |
| Deaths | 0 | 0 | 0 | 0 |
HEMATOLOGY I; HEMOGLOBIN HB G/DL LOW \< 0.85\*PRE-RX; HEMATOCRIT HCT % LOW \< 0.85\*PRE-RX; PLATELET COUNT PLAT X10\*9 C/L LOW \< 0.85\*LLN IF PRE-RX IS MISSING; \< 0.85\*LLN IF PRE-RX \>= LLN; \< 0.85\*PRE-RX IF PRE-RX \< LLN; HIGH \> 1.5\*ULN; HEMATOLOGY II; LEUKOCYTES WBC X10\*3 C/UL LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF LLN \<= PRE-RX \<= ULN; \< 0.85\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.2\*ULN IF PRE-RX IS MISSING; \> 1.2\*ULN IF LLN \<= PRE-RX \<= ULN; \> 1.5\*PRE-RX IF PRE-RX \> ULN; NEUTROPHILS (ABSOLUTE) NEUTA X10\*3 C/UL LOW \< 1.5 IF PRE-RX IS MISSING; \< 1.5 IF PRE-RX \>= 1.5; \< 0.85\*PRE-RX IF; PRE-RX \< 1.5; LYMPHOCYTES (ABSOLUTE) LYMPA X10\*3 C/UL LOW \< 0.75; HIGH \> 7.5; MONOCYTES (ABSOLUTE) MONOA X10\*3 C/UL HIGH \> 2; BASOPHILS (ABSOLUTE) BASOA X10\*3 C/UL HIGH \> 0.4; EOSINOPHILS (ABSOLUTE) EOSA X10\*3 C/UL HIGH \> 0.75; COAGULATION: PROTHROMBIN TIME (PT) PT SEC HIGH \> 1.5\*ULN; APTT APTT SEC HIGH \> 1.5\*ULN; INTL NORMALIZED RATIO (INR) INR FRACTION HIGH \> 1.5\*ULN;
| Participants | Treatment B | Treatment C | Treatment D | Treatment A |
|---|---|---|---|---|
| Hematology I Hemoglobin (G/DL) Abnormal low | 3 | 3 | 2 | 1 |
| Hematocrit (%) Abnormal low | 3 | 4 | 2 | 2 |
| Platelet Count (X10*9 C/L) Abnormal low | 1 | 1 | 2 | 1 |
| Leukocytes (X10*3 C/UL) Abnormal low | 2 | 1 | 0 | 2 |
| Leukocytes (X10*3 C/UL): Abnormal high | 0 | 0 | 1 | 1 |
| Neutrophils (Absolute) (X10*3 C/UL) | 0 | 0 | 2 | 1 |
| Lymphocytes (Absolute) (X10*3 C/UL) Abnormal low | 3 | 4 | 3 | 5 |
| Monocytes (Absolute) (X10*3 C/UL) Abnormal high | 0 | 0 | 0 | 0 |
| Basophils (Absolute) (X10*3 C/UL) Abnormal high | 0 | 0 | 0 | 0 |
| Eosinophils (Absolute) (X10*3 C/UL) | 1 | 1 | 2 | 1 |
| Prothrombin time (PT) (sec): Abnormal high | 1 | 1 | 2 | 0 |
| APTT (sec): Abnormal high | 4 | 25 | 1 | 0 |
| APTT (sec): Not reported | 1 | 0 | 0 | 1 |
| INR (fraction): Abnormal high | 0 | 0 | 0 | 0 |
LIVER \& KIDNEY FUNCTION; ALKALINE PHOSPHATASE (ALP) ALP U/L HIGH \> 1.25\*ULN IF PRE-RX IS MISSING; \> 1.25\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; ASPARTATE AMINOTRANSFERASE (AST) AST U/L HIGH \> 1.25\*ULN IF PRE-RX IS MISSING; \> 1.25\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; ALANINE AMINOTRANSFERASE (ALT) ALT U/L HIGH \> 1.25\*ULN IF PRE-RX IS MISSING; \> 1.25\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; BILIRUBIN, TOTAL TBILI MG/DL HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; BILIRUBIN, DIRECT DBILI MG/DL HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; BLOOD UREA NITROGEN BUN MG/DL HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.2\*PRE-RX IF PRE-RX \> ULN; CREATININE CREAT MG/DL HIGH \> 1.5\*ULN IF PRE-RX IS MISSING; \> 1.5\*ULN IF PRE-RX \<= ULN; \> 1.33\*PRE-RX IF PRE-RX \> ULN;
| Participants | Treatment B | Treatment C | Treatment D | Treatment A |
|---|---|---|---|---|
| ALP (U/L) Abnormal high | 0 | 0 | 0 | 1 |
| AST (U/L) Abnormal high | 0 | 0 | 0 | 0 |
| AST (U/L) Not reported | 0 | 0 | 1 | 0 |
| ALT (U/L) Abnormal high | 0 | 0 | 1 | 0 |
| Bilirubin, Total (MG/DL) Abnormal high | 0 | 0 | 1 | 0 |
| Bilirubin, Direct (MG/DL) Abnormal high | 1 | 1 | 1 | 3 |
| Bilirubin, Direct (MG/DL), Not reported | 1 | 0 | 1 | 0 |
| Blood Urea Nitrogen (MG/DL) Abnormal high | 0 | 1 | 1 | 0 |
| Creatinine (MG/DL) Abnormal high | 0 | 0 | 0 | 0 |
| Creatinine (MG/DL) Not reported | 1 | 0 | 0 | 1 |
ELECTROLYTES: SODIUM, SERUM NA MEQ/L LOW \< 0.95\*LLN IF PRE-RX IS MISSING; \< 0.95\*LLN IF PRE-RX \>= LLN; \< 0.95\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.05\*ULN IF PRE-RX IS MISSING; \> 1.05\*ULN IF PRE-RX \<= ULN; \> 1.05\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN; POTASSIUM, SERUM K MEQ/L LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF PRE-RX \>= LLN; \< 0.9\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.1\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN; CHLORIDE, SERUM CL MEQ/L LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF PRE-RX \>= LLN; \< 0.9\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.1\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN;
| Participants | Treatment B | Treatment C | Treatment D | Treatment A |
|---|---|---|---|---|
| Sodium, Serum (MEQ/L), Abnormal low | 0 | 0 | 0 | 0 |
| Sodium, Serum (MEQ/L), Abnormal high | 0 | 0 | 0 | 0 |
| Potassium, Serum (MEQ/L), Abnormal low | 0 | 0 | 0 | 0 |
| Potassium, Serum (MEQ/L), Abnormal high | 0 | 1 | 1 | 1 |
| Potassium, Serum (MEQ/L), Not reported | 0 | 0 | 1 | 0 |
| Chloride, Serum (MEQ/L) Abnormal low | 0 | 0 | 0 | 0 |
| Chloride, Serum (MEQ/L) Abnormal high | 0 | 0 | 0 | 0 |
| Chloride, Serum (MEQ/L) Not reported | 0 | 0 | 0 | 1 |
ELECTROLYTES (CONT.): CALCIUM, TOTAL CA MG/DL LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF PRE-RX \>= LLN; \< 0.9\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.1\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN; PHOSPHORUS, INORGANIC PHOS MG/DL LOW \< 0.85\*LLN IF PRE-RX IS MISSING; \< 0.85\*LLN IF PRE-RX \>= LLN; \< 0.85\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.25\*ULN IF PRE-RX IS MISSING; \> 1.25\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN; MAGNESIUM, SERUM MG MEQ/L LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF PRE-RX \>= LLN; \< 0.9\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.1\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN
| Participants | Treatment B | Treatment C | Treatment D | Treatment A |
|---|---|---|---|---|
| Calcium, Total (MG/DL) Abnormal low | 0 | 0 | 0 | 1 |
| Calcium, Total (MG/DL) Abnormal high | 0 | 0 | 0 | 0 |
| Phosphorus, Inorganic (MG/DL) Abnormal low | 0 | 1 | 1 | 2 |
| Phosphorus, Inorganic (MG/DL) Abnormal high | 0 | 0 | 0 | 0 |
| Magnesium, Serum (MEQ/L), Abnormal low | 0 | 1 | 0 | 1 |
| Magnesium, Serum (MEQ/L), Abnormal high | 0 | 0 | 0 | 0 |
| Magnesium, Serum (MEQ/L), Not reported | 0 | 0 | 1 | 0 |
GLUCOSE, FASTING SERUM GLUCF MG/DL LOW \< 0.8\*LLN IF PRE-RX IS MISSING; \< 0.8\*LLN IF PRE-RX \>= LLN; \< 0.8\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN; HIGH \> 1.3\*ULN IF PRE-RX IS MISSING \> 1.3\*ULN IF PRE-RX \<= ULN; \> 2\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN; PROTEIN, TOTAL TPRO G/DL LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF PRE-RX \>= LLN; \< 0.9\*PRE-RX IF PRE-RX \< LLN; \< LLN IF PRE-RX \> ULN HIGH \> 1.1\*ULN IF PRE-RX IS MISSING; \> 1.1\*ULN IF PRE-RX \<= ULN; \> 1.1\*PRE-RX IF PRE-RX \> ULN; \> ULN IF PRE-RX \< LLN; ALBUMIN ALB G/DL LOW \< 0.9\*LLN IF PRE-RX IS MISSING; \< 0.9\*LLN IF PRE-RX \>= LLN; \< 0.9\*PRE-RX IF PRE-RX \< LLN; CREATINE KINASE (CK) CK U/L HIGH \> 1.5\*ULN IF PRE-RX IS MISSING; \> 1.5\*ULN IF PRE-RX \<= ULN; \> 1.5\*PRE-RX IF PRE-RX \> ULN; URIC ACID URIC MG/DL HIGH \> 1.2\*ULN IF PRE-RX IS MISSING; \> 1.2\*ULN IF PRE-RX \<= ULN; \> 1.25\*PRE-RX IF PRE-RX \> ULN; LACTATE DEHYDR (LD) LD U/L HIGH \> 1.25\*ULN IF PRE-RX IS MISSING; \> 1.25\*ULN IF PRE-RX \<= ULN; \> 1.5\*PRE-RX IF PRE-RX \> ULN
| Participants | Treatment B | Treatment C | Treatment D | Treatment A |
|---|---|---|---|---|
| Glucose, Fasting serum (MG/DL) Abnormal low | 0 | 0 | 1 | 1 |
| Glucose, Fasting serum (MG/DL) Abnormal high | 2 | 2 | 4 | 4 |
| Protein, Total (G/DL) Abnormal low | 0 | 0 | 1 | 1 |
| Protein, Total (G/DL) Abnormal high | 0 | 0 | 0 | 0 |
| Albumin (G/DL) Abnormal low | 0 | 0 | 1 | 2 |
| Creatine Kinase (CK) (U/L) Abnormal high | 0 | 0 | 0 | 0 |
| Creatine Kinase (CK) (U/L) Not reported | 0 | 0 | 1 | 0 |
| Uric Acid (MG/DL) Abnormal High | 0 | 0 | 0 | 0 |
| LD (U/L) Abnormal high | 0 | 0 | 3 | 0 |
| LD (U/L) Not reported | 0 | 0 | 1 | 0 |
URINALYSIS I; BLOOD, URINE UBLD N/A HIGH \>= 2 IF PRE-RX IS MISSING; \>= 2 IF PRE-RX \< 1; \>= 2 IF PRE-RX \>= 1 SPECIAL STUDIES; OCCULT BLOOD SCREEN, FECES OCBLD N/A HIGH NEGATIVE PRE-RX CHANGING TO POSITIVE
| Participants | Treatment B | Treatment C | Treatment D | Treatment A |
|---|---|---|---|---|
| Blood, Urine (N/A) Abnormal high | 1 | 1 | 0 | 0 |
| Occult Blood Screen, Feces (N/A) Abnormal high | 0 | 0 | 0 | 0 |
Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication.
| Beats/min | Treatment B | Treatment C | Treatment D | Treatment A |
|---|---|---|---|---|
| Day 1 | 1.8 ± 8.6 | 1.4 ± 5.1 | 0.4 ± 8.1 | -0.1 ± 5.4 |
| Day 5 | -2.1 ± 6.9 | 2.0 ± 10.8 | 2.0 ± 8.1 | 1.6 ± 5.9 |
| Day 8 | 0.0 ± 6.9 | -2.8 ± 6.1 | 2.3 ± 4.7 | 4.0 ± 9.8 |
| Day 12 | 0.4 ± 6.0 | 3.9 ± 9.5 | 0.8 ± 2.9 | 1.4 ± 9.5 |
Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication.
| msec | Treatment B | Treatment C | Treatment D | Treatment A |
|---|---|---|---|---|
| Day 1 | -1.3 ± 9.9 | -25.0 ± 67.8 | -6.9 ± 12.6 | 13.6 ± 26.3 |
| Day 5 | 12.6 ± 21.2 | -5.8 ± 8.9 | -5.1 ± 11.8 | -25.4 ± 66.5 |
| Day 8 | -1.2 ± 19.3 | 12.7 ± 25.5 | -22.6 ± 70.3 | -3.4 ± 27.2 |
| Day 12 | -27.7 ± 67.9 | -5.6 ± 8.7 | 8.8 ± 12.4 | -2.6 ± 8.7 |
Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication.
| msec | Treatment B | Treatment C | Treatment D | Treatment A |
|---|---|---|---|---|
| Day 1 | -1.1 ± 6.7 | 5.7 ± 6.2 | -0.2 ± 3.3 | -3.1 ± 11.0 |
| Day 5 | -0.3 ± 14.8 | -0.2 ± 4.6 | -0.2 ± 4.6 | 0.6 ± 4.8 |
| Day 8 | -0.2 ± 4.2 | -1.8 ± 8.8 | -0.7 ± 6.0 | 0.3 ± 8.6 |
| Day 12 | 0.9 ± 6.3 | -0.1 ± 9.3 | -0.7 ± 9.7 | 2.0 ± 7.0 |
Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication.
| msec | Treatment B | Treatment C | Treatment D | Treatment A |
|---|---|---|---|---|
| Day 1 | -3.7 ± 22.2 | -1.6 ± 20.8 | -3.1 ± 24.0 | 3.9 ± 23.2 |
| Day 5 | 8.4 ± 19.3 | -7.4 ± 20.1 | -2.8 ± 22.0 | 5.6 ± 15.9 |
| Day 8 | -1.8 ± 21.3 | 12.0 ± 11.9 | -3.6 ± 24.0 | -7.4 ± 26.8 |
| Day 12 | 0.7 ± 20.1 | -14.9 ± 28.2 | -0.7 ± 10.8 | -2.2 ± 20.4 |
QTcF = QT corrected for heart rate using the Fridericia formula Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication.
| msec | Treatment B | Treatment C | Treatment D | Treatment A |
|---|---|---|---|---|
| Day 1 | -3.2 ± 15.3 | 1.7 ± 13.5 | -1.0 ± 16.5 | 5.7 ± 15.7 |
| Day 5 | 5.1 ± 7.6 | -4.9 ± 11.8 | -0.6 ± 13.1 | 9.9 ± 14.7 |
| Day 8 | -1.3 ± 17.1 | 6.2 ± 6.7 | 0.3 ± 19.7 | -2.1 ± 18.5 |
| Day 12 | 2.1 ± 15.0 | -9.9 ± 22.8 | 0.8 ± 7.1 | 1.0 ± 10.5 |
| mmHg | Treatment B | Treatment C | Treatment D | Treatment A |
|---|---|---|---|---|
| 3 hours post Hemodialysis | -3.7 ± 10.5 | 0.2 ± 10.9 | 0.1 ± 9.0 | 0.5 ± 9.3 |
| 24 hours post dose | -2.8 ± 9.9 | -2.2 ± 8.7 | NA ± NA | NA ± NA |
| mmHg | Treatment B | Treatment C | Treatment D | Treatment A |
|---|---|---|---|---|
| 3 hours post hemodialysis | -6.6 ± 28.2 | 1.1 ± 24.9 | -0.2 ± 17.0 | -5.8 ± 18.0 |
| 24 hours post dose | -8.4 ± 23.7 | -9.2 ± 17.6 | NA ± NA | NA ± NA |
Cmax: Maximum observed plasma concentration
| ng/mL | Treatment B | Treatment C |
|---|---|---|
| Pharmacokinetic Parameters of BMS-986177: Cmax | 1120 ± 391.8 | 3342 ± 922.2 |
| beats/min | Treatment B | Treatment C | Treatment D | Treatment A |
|---|---|---|---|---|
| 3 hours post hemodialysis | 4.9 ± 9.4 | 4.0 ± 7.4 | 4.5 ± 6.5 | 3.3 ± 8.9 |
| 24 hours post dose | 4.2 ± 5.6 | 1.1 ± 7.0 | NA ± NA | NA ± NA |
Time of maximum observed plasma concentration
| h | Treatment B | Treatment C |
|---|---|---|
| Pharmacokinetic Parameters of BMS-986177: Tmax | 4.531 ± 0.933 | 4.855 ± 1.042 |
AUC(0-T) Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration AUC(0-24) Area under the plasma concentration-time curve from time zero to 24 hours
| ng.h/mL | Treatment B | Treatment C |
|---|---|---|
| AUC (0-T) | 10406.6 ± 4551.7 | 36112.9 ± 19802.5 |
| AUC (0-24) | 10533.4 ± 4492.8 | 34028.0 ± 12191.9 |
Fraction of unbound drug
| Percentage | Treatment B | Treatment C |
|---|---|---|
| Pharmacokinetic Parameters of BMS-986177: fu | 7.644 ± 1.257 | 7.868 ± 1.481 |
Maximum observed plasma concentration of free drug
| ng/mL | Treatment B | Treatment C |
|---|---|---|
| Pharmacokinetic Parameters of BMS-986177: Cmaxfu | 84.32 ± 30.14 | 257.9 ± 70.40 |
AUC(0-T)fu Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration of free drug
| ng.h/mL | Treatment B | Treatment C |
|---|---|---|
| Pharmacokinetic Parameters of BMS-986177: Area Under the Concentration Curve AUC (0-T)fu | 783.5 ± 342.1 | 2782.2 ± 1537.7 |
AUC (3-7) : Area under the plasma concentration-time curve from 3 to 7 hours (ie, during dialysis. Determined from blood samples entering and exiting the dialyzer)
| ng.h/mL | Treatment B | Treatment C |
|---|---|---|
| Pharmacokinetic Parameters of BMS-986177: Area Under the Concentration Curve AUC (3-7) | 2847.4 ± 1039.1 | 8558.1 ± 2509.1 |
Collected over From the date of the patient's written consent to participate in the study until 30 days after discontinuation of dosing. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A | 0/32 (0%) | 0/32 (0%) | 0/32 (0%) |
| Treatment B | 0/32 (0%) | 0/32 (0%) | 0/32 (0%) |
| Treatment C | 0/31 (0%) | 0/31 (0%) | 0/31 (0%) |
| Treatment D | 0/31 (0%) | 0/31 (0%) | 0/31 (0%) |
| Age, Continuous(Years) | Seq ABCD | Seq BDAC | Seq CADB | Seq DCBA | Total |
|---|---|---|---|---|---|
| Mean | 55.1 ± 7.3 | 55.6 ± 6.6 | 52.0 ± 12.4 | 51.7 ± 9.9 | 53.6 ± 8.9 |
| Sex: Female, Male(Participants) | Seq ABCD | Seq BDAC | Seq CADB | Seq DCBA | Total |
|---|---|---|---|---|---|
| Female | 1 | 5 | 3 | 3 | 12 |
| Male | 6 | 4 | 4 | 6 | 20 |
| Ethnicity (NIH/OMB)(Participants) | Seq ABCD | Seq BDAC | Seq CADB | Seq DCBA | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 7 | 9 | 7 | 9 | 32 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Seq ABCD | Seq BDAC | Seq CADB | Seq DCBA | Total |
|---|---|---|---|---|---|
| White | 1 | 0 | 1 | 1 | 3 |
| Black or African American | 6 | 9 | 6 | 8 | 29 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2017 to primary completion in Oct 2017, 5 months.
Results were first posted in Dec 2020, 3 years 2 months after primary completion. A results delay was requested in Nov 2018.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Milvexian